# Hepatology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Joe Frazier (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX004-SYN-TD
- Date: 2008-03-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Anjali Deshpande, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Clarence Whitfield, MD

## Reason for consultation

High FIB-4 (3.43) with a mildly raised AST and low platelets at the yearly liver check in a 64-year-old man with type 2 diabetes, hypertension, low HDL, high triglycerides and obesity, who drinks little. Please stage his liver disease with elastography and advise on surveillance and treatment. **S**

## History

Mr. Frazier, a 64-year-old former professional boxer, is seen at the request of Dr. Whitfield for a FIB-4 of 3.43 found at his yearly diabetes check. He feels well and has had no jaundice, abdominal or leg swelling, black stools, vomiting of blood or confusion. He drinks one or two beers on some weekends and has never drunk heavily. He has had diabetes for about twelve years and high blood pressure for many years. He has never had a blood transfusion or used injected drugs. He wants to keep working at his gym. **S**

## Examination

| System | Finding |
|---|---|
| General | Well; blood pressure 148/90, pulse 74; BMI 31.3 |
| Abdomen | Liver edge firm at the costal margin; spleen tip not felt; no ascites |
| Skin | No jaundice, spider angiomas or palmar erythema |
| Neurological | No asterixis |

BP 148/90 mmHg; pulse 74 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 103.6 kg; BMI 31.3 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Whitfield's intake note and results: AST 48, ALT 42 U/L, alkaline phosphatase 96, albumin 4.0 g/dL, bilirubin 0.9 mg/dL, platelets 138, creatinine 1.08 mg/dL, FIB-4 3.43. Today: transient elastography with a median liver stiffness of 17.6 kPa (interquartile range 14%) and a controlled attenuation parameter of 318 dB/m; ultrasound with a coarse, echogenic, mildly nodular liver, a spleen of 13.4 cm, a patent portal vein, no ascites and no focal lesion; INR 1.1; AFP 4.2 ng/mL. Hepatitis B surface antigen, core antibody and surface antibody negative; hepatitis A antibody negative; hepatitis C antibody and HIV nonreactive; ferritin and transferrin saturation normal; antinuclear and smooth muscle antibodies negative. Liver stiffness (transient elastography): 17.6 kPa (high); INR: 1.1; Alpha-fetoprotein (AFP): 4.2 ng/mL. All results are synthetic.

## Assessment

1. **Metabolic dysfunction-associated steatotic liver disease** (K76.0). Steatosis with diabetes, obesity, low HDL and high triglycerides and little alcohol meets the definition of MASLD. Other causes have been excluded by the tests above. **S**
2. **Compensated cirrhosis** (K74.69). A FIB-4 above 2.67 followed by a liver stiffness of 17.6 kPa, with platelets of 138, a nodular liver and a large spleen, is consistent with compensated advanced chronic liver disease, most likely cirrhosis. A biopsy would not change management. Child-Pugh A (5 points), MELD 8. There is no sign of decompensation. **S**
3. **Liver cancer surveillance** (K74.69). Cirrhosis from MASLD carries a risk of hepatocellular carcinoma high enough to justify surveillance by ultrasound with AFP every six months; today's baseline is clear and of good quality. Surveillance on time is what finds cancer when it can still be cured. **S**
4. **Portal hypertension** (K74.69). A stiffness between 15 and 25 kPa with platelets below 150 cannot rule clinically significant portal hypertension in or out, so an upper endoscopy to look for varices is advised; a beta-blocker would be started if varices needing treatment are found. **S**
5. **Diabetes and the liver** (E11.65). A GLP-1 receptor agonist such as semaglutide is favored: it lowers glucose and weight, has cardiovascular and kidney benefit, and improves steatohepatitis. Metformin is safe to continue in compensated cirrhosis with normal kidney function, and atorvastatin is safe and beneficial. Sulfonylureas and insulin are not needed and carry a risk of low blood sugar. **S**

## Recommendations

1. Liver ultrasound with AFP every six months, starting with today's baseline.
2. Upper endoscopy to screen for varices within the next six weeks; if none are found and the liver injury continues, repeat in two years.
3. Start semaglutide and increase it as tolerated; continue metformin and atorvastatin 40 mg.
4. Aim for 7 to 10% weight loss over a year.
5. No alcohol at all; no ibuprofen or naproxen; acetaminophen no more than 2 g a day.
6. Hepatitis A and B vaccine series and PCV20 now; influenza, COVID-19 and RSV vaccines in season.
7. Albumin, bilirubin, platelets and kidney function every six months; repeat elastography in one year.
8. Teach the warning signs of decompensation: abdominal or leg swelling, black stools or vomiting of blood, confusion, yellowing.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Whitfield, who saw him the same day. The diagnosis and plan were explained to Mr. Frazier, who agreed and asked for a written list of the warning signs, which was given. **S**

## Follow-up

Hepatology review of the six-month ultrasound and AFP, a visit with repeat elastography at one year, and sooner for any warning sign; Dr. Whitfield continues primary care. **S**

## Guideline basis

- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023), American Association for the Study of Liver Diseases (Hepatology 2023;77(5))
- AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023), American Association for the Study of Liver Diseases (Hepatology 2023;78(6))
- Baveno VII - Renewing consensus in portal hypertension (2022), Baveno VII Faculty (Journal of Hepatology 2022;76(4))
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
